


# BMJ Open Community-acquired pneumonia: use of clinical characteristics of acutely admitted patients for the development of a diagnostic model – a cross-sectional multicentre study

Mariana B Cartuliales <sup>1,2</sup>, Christian Backer Mogensen,<sup>1,2</sup> Flemming S Rosenvinge,<sup>3,4</sup> Thor Aage Skovsted,<sup>5</sup> Morten Hjarnø Lorentzen,<sup>1,2</sup> Anne Heltborg,<sup>1,2</sup> Mathias Amdi Hertz,<sup>6,7</sup> Frida Kaldan,<sup>1</sup> Jens Juel Specht,<sup>1</sup> Helene Skjøt-Arkil<sup>1,2</sup>

**To cite:** Cartuliales MB, Mogensen CB, Rosenvinge FS, *et al.* Community-acquired pneumonia: use of clinical characteristics of acutely admitted patients for the development of a diagnostic model – a cross-sectional multicentre study. *BMJ Open* 2024;**14**:e079123. doi:10.1136/bmjopen-2023-079123

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2023-079123>).

Received 22 August 2023  
Accepted 20 May 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Mariana B Cartuliales;  
mbc@rsyd.dk

## ABSTRACT

**Objectives** This study aimed to describe the clinical characteristics of adults with suspected acute community-acquired pneumonia (CAP) on hospitalisation, evaluate their prediction performance for CAP and compare the performance of the model to the initial assessment of the physician.

**Design** Cross-sectional, multicentre study.

**Setting** The data originated from the Infectious DisEases in Emergency Departments study and were collected prospectively from patient interviews and medical records. The study included four Danish medical emergency departments (EDs) and was conducted between 1 March 2021 and 28 February 2022.

**Participants** A total of 954 patients admitted with suspected infection were included in the study.

**Primary and secondary outcome** The primary outcome was CAP diagnosis assessed by an expert panel.

**Results** According to expert evaluation, CAP had a 28% prevalence. 13 diagnostic predictors were identified using least absolute shrinkage and selection operator regression to build the prediction model: dyspnoea, expectoration, cough, common cold, malaise, chest pain, respiratory rate ( $>20$  breaths/min), oxygen saturation ( $<96\%$ ), abnormal chest auscultation, leucocytes ( $<3.5 \times 10^9/L$  or  $>8.8 \times 10^9/L$ ) and neutrophils ( $>7.5 \times 10^9/L$ ). C reactive protein ( $<20$  mg/L) and having no previous event of CAP contributed negatively to the final model. The predictors yielded good prediction performance for CAP with an area under the receiver-operator characteristic curve (AUC) of 0.85 (CI 0.77 to 0.92). However, the initial diagnosis made by the ED physician performed better, with an AUC of 0.86 (CI 84% to 89%).

**Conclusion** Typical respiratory symptoms combined with abnormal vital signs and elevated infection biomarkers were predictors for CAP on admission to an ED. The clinical value of the prediction model is questionable in our setting as it does not outperform the clinician's assessment. Further studies that add novel diagnostic tools and use imaging or serological markers are needed to improve a model that would help diagnose CAP in an ED setting more accurately.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This was a multicentre study with prospectively collected data.
- ⇒ Least absolute shrinkage and selection operator regression was used to establish a score for community-acquired pneumonia (CAP), and the performance of the diagnostic model was evaluated using the area under the receiver operating characteristic curve and calibration curves.
- ⇒ This diagnostic prediction model could have been improved by adding other diagnostic tools, such as imaging or serological markers.
- ⇒ Lack of external validation of the model using the clinical score for CAP was a limitation.

**Trial registration number** NCT04681963.

## INTRODUCTION

Community-acquired pneumonia (CAP) is an increasing cause of hospitalisation and mortality, especially among elderly patients.<sup>1–5</sup> Early diagnosis and accurate treatment at the emergency department are essential to avoid serious complications such as bacteraemia, sepsis, organ failure and death<sup>6</sup> and to fight antimicrobial resistance.<sup>7</sup>

The diagnosis of CAP generally requires a new infiltrate on a chest X-ray with a clinically compatible syndrome (eg, fever, dyspnoea, cough and sputum production).<sup>8</sup> These symptoms are not sufficient to diagnose or exclude CAP, as they overlap with other diseases<sup>8</sup> and can be subtle in patients with advanced age and/or impaired immune systems.<sup>9 10</sup> The chest X-ray is an imprecise diagnostic tool for CAP, risking under/overdiagnosis<sup>11 12</sup> and might not be the optimal reference standard

for CAP. This variability in clinical signs and symptoms combined with non-specific diagnostic tools,<sup>12</sup> biomarkers<sup>13 14</sup> and time-consuming microbiological tests<sup>9</sup> challenges physicians in differentiating CAP from other infections.<sup>10 15</sup>

The CAP population today has also changed with increased ageing,<sup>16</sup> multimorbidities<sup>17</sup> and immunomodulatory treatments. Therefore, our knowledge of CAP symptoms and signs needs to be adapted to the actual population.

Previously, prediction models for the diagnosis of CAP were developed on prognostic factors, including severity assessment,<sup>18 19</sup> observations in a primary care setting only<sup>20-22</sup> or a reference diagnosis based solely on the registered discharge diagnosis in the medical record or positive chest X-ray findings.<sup>22 23</sup> A valid outcome diagnosis was essential. However, in pragmatic studies, an expert panel using available information has been deemed a better reference standard.<sup>11</sup>

Therefore, there is a need to describe the clinical characteristics of the current population of patients admitted with suspected CAP and develop a diagnostic model that includes physical examination, blood tests, vital signs, patient medical history and healthcare expertise. Given the current diagnostic tool inaccuracies, an expert-panel-based diagnostic model was expected to surpass the emergency department (ED) physicians' initial accuracy.

### Hypothesis and objectives

We hypothesised that a diagnostic prediction model based on well-defined clinical characteristics could assist an ED physician to make an earlier, more precise CAP diagnosis. Therefore, the aim was to identify the clinical characteristics of adults admitted with CAP and evaluate the performance of these characteristics in a prediction model.

The objectives were as follows:

- ▶ To compare clinical characteristics of patients with a CAP diagnosis from (1) all patients admitted with suspected infection and (2) patients suspected of CAP.
- ▶ To develop and evaluate a diagnostic model to identify patients with CAP among ED patients suspected of infection and to compare the performance of the model to the initial assessment of the ED physician.

### METHODS

The study was reported following 'The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis' (TRIPOD) statement.<sup>24</sup> The protocol was registered by the Danish Data Protection Agency (No 20/60508) and in ClinicalTrials.gov (NCT04681963).

### Study design, source of data and setting

This study had an analytical, cross-sectional, multicentre design. The data were collected prospectively and originated from the Infectious DisEases in Emergency Departments (INDEED) study. The published study protocol

provides further detailed information.<sup>25</sup> Four Danish medical EDs participated, with a catchment area of around 775 000 inhabitants, between 1 March 2021 and 28 February 2022.

In Denmark, patients can be directed to various specialties within the ED, for example, medical, gastrointestinal surgery, cardiology, orthopaedics, gynaecology, psychiatry and intensive care.<sup>26</sup> Suspected infection cases are usually assigned to a medical ED.

### Participants

Adult patients ( $\geq 18$  years) admitted to a medical ED were eligible to participate. Patients were included if the ED physician suspected infection and the patient could provide verbal and written consent. The exclusion criteria were as follows: (1) need for urgent, life-saving treatment, (2) transferal to intensive care, (3) admission within the last fortnight, (4) verified SARS-CoV-2 infection at the time of admission or within 14 days before admission, (5) severe immunodeficiencies (HIV positive, with a cluster of differentiation 4 cell count  $< 200$ ) or treatment with immunosuppressive medicine (Anatomical Therapeutic Chemical classification L04A), corticosteroids ( $> 20$  mg/day prednisone or equivalent for  $> 14$  days within the last 30 days) or chemotherapy within 30 days.

### Recruitment and data collection

Six project assistants with healthcare backgrounds (three physicians, one physiotherapist and two final-year medical students) were responsible for inclusion and data collection from Mondays to Fridays, 08:00 to 20:00. The population was a convenient sample of eligible patients consecutively identified from the patient management system by a project assistant. Immediately following the initial clinical assessment, the project assistant asked the ED physician whether an infection was suspected and the most likely infection focus (CAP, urinary tract infection or unknown origin). Generally, the clinical assessment took place within the first 30 min of admission before blood tests or imaging were ordered, and therefore, the ED physician often relied only on information from the patient's signs, symptoms and vital parameters. The study assistant collected verbal and written consent from eligible patients. All data collected were registered in the electronic study database REDCap (Research Electronic Data Capture).<sup>27</sup>

### Reference diagnosis

The reference diagnosis was the diagnosis of CAP assessed by an expert panel. The expert panel consisted of eight clinical experts at consultant level in the fields of infectious diseases and emergency medicine working in pairs. They conducted a patient file audit and determined the final diagnosis based on all clinical information registered within the first week of ED admission. The information included routine laboratory tests of blood, urine and sputum. In addition, PCR tests of sputum, urine flow cytometry, chest X-ray and chest CT were available

for some patients. The experts had access to all images, including the radiologist's interpretation and documentation. The experts were blinded to each other and independently registered their assessments in a standardised electronic template<sup>27</sup> in the study database. In case of disagreement, the two specialists re-evaluated the medical record and collectively reached a consensus.

### Predictors

All clinical characteristics were collected on arrival at the ED. Symptoms, demographic data and lifestyle factors were registered during a standardised bedside interview with the patient. In addition, information about vital parameters, comorbidities, medical treatment and blood tests was collected from the patient's medical record. The project assistants collecting data were blinded to the final diagnosis.

70 candidate predictors were selected from the literature and discussed with the specialists and project group.<sup>20 28–37</sup> The prespecified potential predictors with measurement units, groups, cut-offs and considerations/assumptions of inclusion were selected (see online supplemental table S1).

- ▶ Demographic information, lifestyle factors and comorbidities: age, sex, civil status, employment, nursing home residence, smoking, alcohol consumption, Body Mass Index (BMI), level of physical activity, activities of daily living score, dementia, respiratory, neurological, cardiovascular, endocrinological, nephrological and gastrointestinal comorbidities were collected.
- ▶ Patient symptoms 2 weeks before admission: malaise, fatigue, headache, dizziness, altered mental status, for example, confusion, dyspnoea, malnutrition, cough, secretions from the respiratory tract, sore throat, common cold, fever feeling, chest pain, peripheral oedema, nausea, vomiting, decreased appetite, abdominal pain, diarrhoea and pain in muscles and joints including back pain were collected.
- ▶ Severity assessment, clinical parameters with cut-offs based on National Early Warning Score<sup>38</sup> used at the arrival of the ED and the use of medications: CURB-65  $\geq 3$  (confusion, uraemia, respiratory rate, blood pressure, age  $>65$  years), triage,<sup>39</sup> Glasgow Coma Scale, oxygen saturation  $<96\%$ , heart rate  $<51$  or  $>90$  beats/min, blood pressure (systolic  $<111$  or  $>219$ , diastolic  $\leq 60$  mm Hg), respiratory rate  $>20$  breaths/min, temperature  $>38^\circ\text{C}$ , abnormal chest auscultation, abdominal tenderness, polypharmacy ( $\geq 5$  medications), use of analgesics and vaccination status (SARS-CoV-2, pneumococcus, influenza) were recorded.
- ▶ Blood tests with cut-offs routinely applied at our institutions: haematocrit (%), haemoglobin (mmol/L), leucocytes ( $10^9/\text{L}$ ), platelets ( $10^9/\text{L}$ ), neutrophils ( $10^9/\text{L}$ ), lymphocytes ( $10^9/\text{L}$ ), albumin g/L, creatinine ( $\mu\text{mol}/\text{L}$ ), blood urea nitrogen (mmol/L), sodium (mmol/L), prothrombin, bilirubin ( $\mu\text{mol}$ ),

glucose (mmol/L) and C reactive protein (CRP) (mg/L) were recorded.


### Statistical methods

The study sample size was estimated using data from the University Hospital of Southern Denmark. We estimated a need for at least 700 patients admitted with suspected infection. Of those, 400 patients should have suspected CAP and 200 patients should have verified CAP to complete a reasonable multivariable regression analysis. Descriptive statistics for baseline characteristics of the patients were conducted for the 70 potential predictors based on the data from the INDEED study.<sup>25</sup> Data were presented as means and SDs, or medians and IQRs for continuous variables, and numbers (n) and percentages (%) for categorical and binary variables. Extensive univariate logistic regression analyses were performed to examine the unadjusted association between each candidate predictor and the outcome CAP. Results of univariate analyses were reported with OR, 95% CIs and statistical significance levels were two-sided reported with a p value of  $<0.05$  to present a descriptive overview of the individual's associations in the population. Complete case analyses were performed, and the predictors were dichotomised or categorised and presented with percentages (%) for inclusion in the final model. The least absolute shrinkage and selection operator (LASSO) multivariable regression was performed with a random split-sample to develop and validate the model, using 20% of the data for internal cross-validation. The model calibration was assessed using a likelihood ratio test, and recalibration was done based on the calibration belt and the optimal predicted proportion. In the model, age ( $\geq 75$  years old) was considered an effect modifier based on several studies showing differences in symptoms and signs of a CAP diagnosis in older adults.<sup>33 40–42</sup> An exploratory approach was conducted for the clinical characteristics to achieve the model with the best predictive performance, testing performances with continuous, dichotomous or categorical variables. In addition, the receiver-operator characteristic (ROC) curve was created to estimate the model's accuracy, and the area under the curve (AUC) visualised any discrimination between true positives and negatives. The sensitivity, specificity and positive and negative predictive values with 95% CI were calculated using the best threshold criteria of the predicted probability of the ROC curve. The same threshold was implemented in developing a CAP score, including the predictor variables. A CAP score  $>0$  represents the presence of CAP, and  $<0$  indicates the absence of CAP. Sensitivity, specificity and positive and negative predictive values with 95% CI were calculated from the initial diagnosis made by the ED physician. Analyses were performed using STATA V.17.0 (Texas, USA).

### Patient and public involvement

Patients and/or the public were not directly involved in this study.





**Figure 1** Trial population, green boxes showing the numbers of patients with CAP. CAP, community-acquired pneumonia.

## RESULTS

### Participants

We recruited 954 patients admitted to the ED with suspected infection, representing 43% of the population screened for eligibility. Of those, the attending physician suspected that 402 (42%) had a CAP diagnosis. The expert panel verified a CAP diagnosis in 265 (28%) of the recruited patients (figure 1). The evaluation of 332 chest CT scans showed that 188 (57%) patients had verified pneumonia, and from those, 148 (76%) had CAP assessed by the expert panel and confirmed by a chest CT scan. Most patients (65%) with CAP were discharged to an internal medicine ward, while 29% of the patients diagnosed with CAP by the expert panel were discharged directly home. There were 2.5%, 2.5% and 1.0% of the population with CAP that were discharged to the intensive care unit (ICU), surgical and other wards, respectively.

### Characteristics of patients with suspected infections

We compared the clinical characteristics of patients with verified CAP to patients with suspected infection (954). Median age for patients with verified CAP was 75 years (IQR 63.5; 82.0), and over half admitted with suspected infection were males (53.8%). Univariate analysis revealed that patients with verified CAP were more often previous smokers (OR 1.83 (CI 1.30 to 2.57),  $p < 0.001$ ) with smoking history compared with suspected infection cases. Strongly independent predictors for CAP were symptoms such as dyspnoea, cough, expectoration, chest pain and cold symptoms (all  $p < 0.001$ ). Compared with

patients without CAP, the risk of having CAP increased fivefold if the patient had chest auscultation abnormalities (OR 5.67 (CI 4.15 to 7.75),  $p < 0.001$ ) and decreased by half in case of abdominal tenderness by palpation (OR 0.52 (CI 0.35 to 0.78),  $p = 0.002$ ). Patients with CAP often had comorbidities related to other pulmonary diseases ( $p < 0.001$ ) and often had previous CAP infections ( $p < 0.001$ ). These patients were more acutely ill when assessed by triage ( $p < 0.001$ ), with fever  $> 38^{\circ}\text{C}$  ( $p = 0.036$ ), higher respiratory rate (median 20.0 (IQR 18.0; 24.0),  $p < 0.001$ ), higher heart rate (mean 93.2 (SD 18.9),  $p < 0.001$ ) and lower oxygen saturation (median 95.0 (IQR 93.0; 97.0),  $p < 0.001$ ). Patients with verified CAP had a median CRP of 125.0 (IQR 57.0; 203.5) versus 82.0 (IQR 19.0; 172.0) ( $p < 0.001$ ) compared with the rest of the population and higher levels of neutrophils ( $p < 0.001$ ) and leucocytes ( $p < 0.001$ ). Furthermore, lymphocytes yielded a  $p$  value of 0.018. Patients with verified CAP were more often vaccinated against SARS-CoV-2 ( $p = 0.033$ ) and influenza ( $p = 0.025$ ), but no differences were found regarding pneumococcal vaccination. Table 1 presents the characteristics of the population with statistically significant results of the unadjusted association between each predictor for patients with verified and not verified CAP. See online supplemental table S2 for the 70 exploratory results from continuous, dichotomous and categorical variables tested in the diagnostic prediction model.

**Table 1** Characteristics of the population with suspected infection (n=954)

Characteristics	Patients suspected of infection at admission			OR (95% CI)	P value
	CAP n (%)	Not CAP n (%)	Missings n (%)		
Total of patients	265 (27.8)	689 (72.2)	0 (0.0)	–	–
<b>Lifestyle factors</b>					
Smoking status			33 (3.5)		
No	66 (26.0)	257 (38.5)		1 (reference)	
Current smoker	54 (21.3)	125 (18.7)		1.68 (1.10 to 2.55)	0.015
Previous smoker	134 (52.8)	285 (42.7)		1.83 (1.30 to 2.57)	<0.001
<b>Symptoms</b>					
Malaise	173 (67.8)	386 (58.7)	41 (4.3)	1.48 (1.09 to 2.01)	0.010
Dyspnoea	171 (67.3)	208 (31.5)	39 (4.1)	4.48 (3.29 to 6.11)	<0.001
Cough	173 (68.1)	185 (28.0)	39 (4.1)	5.49 (4.01 to 7.52)	<0.001
Expectoration	140 (55.1)	139 (21.0)	39 (4.1)	4.61 (3.38 to 6.28)	<0.001
Sore throat	39 (15.4)	65 (9.8)	39 (4.1)	1.66 (1.08 to 2.54)	0.019
Common cold	45 (17.7)	50 (7.6)	39 (4.1)	2.63 (1.70 to 4.05)	<0.001
Chest pain	71 (28.1)	97 (14.7)	40 (4.2)	2.26 (1.60 to 3.21)	<0.001
Oedema	10 (4.0)	69 (10.4)	40 (4.2)	0.35 (1.17 to 0.69)	0.002
Vomiting	40 (15.8)	150 (22.6)	38 (4.0)	0.64 (0.43 to 0.94)	0.023
Gastrointestinal pain	40 (15.8)	153 (23.1)	38 (4.0)	0.62 (0.42 to 0.91)	0.016
Muscular pain	79 (31.3)	265 (40.3)	44 (4.6)	0.67 (0.49 to 0.92)	0.013
<b>Comorbidities</b>					
Pulmonary diseases	105 (39.6)	164 (23.8)	0 (0.0)	2.10 (1.55 to 2.84)	<0.001
Prior pneumonia			100 (10.5)		
No	79 (33.3)	331 (53.6)		1 (reference)	
Yes, one time	50 (21.1)	130 (21.1)		1.61 (1.07 to 2.42)	0.022
Yes, more than one time	108 (45.6)	156 (25.3)		2.90 (2.05 to 4.10)	<0.001
<b>Vaccinations</b>					
SARS-CoV-2†	222 (83.8)	534 (77.5)	0 (0.0)	1.49 (1.03 to 2.17)	0.033
Influenza	191 (72.1)	444 (64.4)	0 (0.0)	1.42 (1.04 to 1.94)	0.025
<b>Clinical assessment</b>					
Abnormal chest auscultation*	168 (65.4)	161 (25.0)	52 (5.4)	5.67 (4.15 to 7.75)	<0.001
Abdominal tenderness	37 (15.0)	155 (25.0)	86 (9.0)	0.52 (0.35 to 0.78)	0.002
<b>Severity assessment</b>					
Triage‡			59 (6.2)		
Green/blue	37 (14.8)	146 (22.6)		1 (reference)	
Yellow	126 (50.4)	353 (54.7)		1.40 (0.93 to 2.13)	0.105
Red/orange	87 (34.8)	146 (22.6)		2.35 (1.50 to 3.67)	<0.001
<b>Vital parameters</b>					
Respiratory rate >20 breaths/min	124 (47.0)	161 (23.5)	5 (0.5)	2.88 (2.13 to 3.88)	<0.001
Oxygen saturation <96%	162 (61.1)	231 (33.7)	4 (0.4)	3.09 (2.30 to 4.14)	<0.001
Heart rate <51 or >90 beats/min	148 (55.8)	312 (45.3)	1 (0.1)	1.52 (1.14 to 2.02)	0.003
Fever >38°C	77 (29.3)	156 (22.7)	5 (0.5)	1.40 (1.02 to 1.93)	0.036
<b>Blood tests</b>					
Leucocytes <3.5×10 <sup>9</sup> /L or >8.8×10 <sup>9</sup> /L	214 (80.8)	456 (66.2)	0 (0.0)	2.14 (1.52 to 3.02)	<0.001

Continued

**Table 1** Continued

Characteristics	Patients suspected of infection at admission			OR (95% CI)	P value
	CAP n (%)	Not CAP n (%)	Missings n (%)		
Neutrophils >7.5×10 <sup>9</sup> /L	187 (71.1)	362 (53.2)	10 (1.0)	2.16 (1.59 to 2.94)	<0.001
Lymphocytes‡ <1.00×10 <sup>9</sup> /L or >4.00×10 <sup>9</sup> /L	53 (55.2)	92 (40.9)	633 (66.3)	1.78 (1.10 to 2.88)	0.018
C reactive protein (mg/L)			0 (0.0)		
<20 mg/L	21 (7.9)	175 (25.4)		1 (reference)	
21–99 mg/L	86 (32.5)	205 (29.8)		3.49 (2.08 to 5.86)	<0.001
≥100 mg/L	158 (59.6)	309 (44.8)		4.26 (2.60 to 6.96)	<0.001

The predictors in the table are those dichotomised or categorised as they were later incorporated into the final diagnostic model. Only statistically significant results of the unadjusted association between each candidate predictor and the outcome CAP are presented.

\*Abnormal chest auscultation: any abnormal findings such as crackles and rhonchi.

†Triage: Danish emergency process triage.<sup>39</sup>

‡Variables not included in the multivariate model.

CAP, community-acquired pneumonia.

### Characteristics of patients suspected of CAP

Using the 70 candidate predictors, we compared the clinical characteristics of patients with verified CAP to patients with suspected but not verified CAP (402).

Statistically significant differences are shown in [table 2](#). Of the 402 patients with suspected CAP, half of the patients, 229 (57%) had verified CAP. Patients with suspected CAP had a median age of 74.0 (IQR 62.0; 82.0), and half were male (52.7%). Patients with verified CAP reported more respiratory symptoms, such as cough (p=0.009) and expectoration (p=0.037), and more gastrointestinal symptoms, such as nausea (p=0.033) and loss of appetite (p=0.030), compared with those without CAP. Fewer patients with verified CAP had a CURB-65 ≥3 (p=0.047), and more patients had oxygen saturation <96% (p<0.001), a heart rate of <51 or >100 beats/min (p=0.045) and fever>38°C (p=0.011). Elevated infection biomarkers (leucocytes, neutrophils, CRP, all p<0.001) and plasma sodium (p<0.001) were highly associated with CAP. Fewer patients with CAP had plasma bilirubin values of <5 or >25 mmol/L (p=0.045) ([table 2](#)).

### Model development and performance

We developed a prediction model for diagnosing pneumonia in patients admitted with suspected infection (n=954) and compared it with the clinician's presumptive diagnosis. Online supplemental table S3 presents the characteristics of the population randomised in the training and validation sets.

The predictors associated with CAP in our final model are presented in [table 3](#).

The model performance yielded an AUC of 0.85 (CI 0.77 to 0.92), and the calibration of the model yielded p=0.227 after recalibration, demonstrating a good prediction of the proportion of patients with CAP in the test sample (online supplemental figures S1 and S2).

Based on a lambda result of  $\lambda=0.0402856$  and a probability threshold of 0.35, the LASSO calculation with characteristics predictive of CAP and the calculation of the final model with a cut-off value greater than 0 indicating the diagnosis CAP are presented in supplemental material (online supplemental formulas S1 and S2).

At the optimal cut-off of 0.35, the prediction model yielded an 86.1% sensitivity and 64.1% specificity. Based on the trial population ([figure 1](#)), the sensitivity of the prediction model was comparable to the initial diagnosis made by the ED physicians. However, the specificity and positive predictive value were significantly lower ([table 4](#)).

### Model specification

The final model did not include the following possible predictors: lymphocytes, SARS-CoV-2 and BMI. The reasons were a high percentage of missings (lymphocytes 66.3%), clinical relevance and statistical performance (BMI and SARS-CoV-2). These considerations are described in detail in online supplemental material.

### DISCUSSION

More than every fourth patient with suspected infection was diagnosed with CAP (28%). The ED physicians suspected CAP in almost half (42%) of patients admitted with suspected infection. Patients with suspected CAP included 57% with a final expert diagnosis of CAP and 43% without CAP. We have identified 27 clinical characteristics for patients diagnosed with CAP among those admitted suspected of infection. Patients with CAP were characterised more often with a history of smoking, previous CAP, respiratory symptoms, abnormal lung auscultation, worse triage and abnormal levels of infection biomarkers. Fewer clinic characteristics (13) were identified for patients diagnosed with CAP among patients suspected of CAP by the ED physician and included typical respiratory

**Table 2** Characteristics of the population with suspected CAP (n=402) by the physician at admission

Characteristics	Patients suspected of CAP at admission			OR (95% CI)	P value
	CAP n (%)	Not CAP n (%)	Missings n (%)		
Total of patients	229 (57.0)	173 (43.0)	0 (0.0)		
<b>Symptoms</b>					
Cough	168 (75.7)	104 (63.4)	16 (4.0)	1.79 (1.15 to 2.79)	0.009
Expectoration	132 (59.5)	80 (48.8)	16 (4.0)	1.54 (1.02 to 2.31)	0.037
Nausea	70 (31.8)	36 (22.0)	18 (4.5)	1.65 (1.04 to 2.64)	0.033
Loss of appetite	137 (62.3)	84 (51.2)	18 (4.5)	1.57 (1.04 to 2.36)	0.030
<b>Severity assessment</b>					
CURB-65 $\geq 3^*$	23 (10.4)	30 (17.3)	8 (2.0)	0.55 (0.30 to 0.99)	0.047
<b>Vital parameters</b>					
Oxygen saturation <96%	147 (64.2)	79 (46.0)	1 (0.2)	2.11 (1.40 to 3.15)	<0.001
Heart rate <51 or >100 beats/min	129 (56.3)	80 (46.2)	0 (0.0)	1.49 (1.00 to 2.23)	0.045
Fever >38°C	64 (28.2)	30 (17.3)	2 (0.5)	1.87 (1.14 to 3.05)	0.011
<b>Blood tests</b>					
Leucocytes <3.5×10 <sup>9</sup> /L or >8.8×10 <sup>9</sup> /L	191 (83.4)	106 (61.3)	0 (0.0)	3.17 (1.99 to 5.04)	<0.001
Neutrophils >7.5×10 <sup>9</sup> /L	166 (73.1)	81 (47.6)	5 (1.2)	2.99 (1.96 to 4.55)	<0.001
Sodium <137 or >145 mmol/L	114 (49.8)	55 (31.8)	0 (0.0)	2.12 (1.40 to 3.21)	<0.001
Bilirubin <5 or >25 mmol/L	32 (14.0)	37 (21.8)	4 (1.0)	0.58 (0.34 to 0.98)	0.045
C reactive protein (mg/L), n (%)			0 (0.0)		
<20 mg/L	15 (6.6)	59 (34.1)		1 (reference)	
21–99 mg/L	74 (32.3)	64 (37.0)		4.54 (2.35 to 8.78)	<0.001
≥100 mg/L	140 (61.1)	50 (28.9)		11.01 (5.73 to 21.14)	<0.001

Statistically significant results from the unadjusted association between each candidate predictor and the outcome CAP.  
 \*CURB-65: confusion, uraemia, respiratory rate, blood pressure, age >65 years.  
 CAP, community-acquired pneumonia.

symptoms but also gastrointestinal symptoms, abnormal vital signs, increased blood markers and lower CURB-65 scores. The final diagnostic prediction model yielded 13 diagnostic predictors for CAP recognised by the literature. The model performance was similar to the diagnosis made by the ED physicians regarding sensitivity and negative predictive value but not as good in determining the specificity and positive predictive values.

Our prediction model had a good performance (AUC 0.85) and calibration ( $p=0.227$ ), and with the best cut-off at 35%, the sensitivity reached 86.1% and specificity 64.1%. Therefore, the model could be tested externally at other sites, especially where clinicians are not always available due to the lack of resources, and contribute to the initial management of CAP, guiding further clinical investigation. In this study, ED physicians relied on the patient's history and the results from a simple clinical examination to diagnose CAP with a comparable negative predictive value (93% vs 94%) and a better positive predictive value (57% vs 42%). Even though our model is not entirely comparable to the initial diagnosis made by the ED physicians due to the difference in the prevalence

of CAP, our results are similar to a recent systematic review.<sup>43</sup> Other studies reported that ED physicians' accuracy in diagnosing CAP ranged from 76% to 96%,<sup>44</sup> and artificial intelligence predicted the presence of pneumonia with a sensitivity of 94% and specificity of 50%.<sup>45</sup> These results show that there is room for improvement in diagnosing CAP. It could be achieved by including additional predictors such as biomarkers, for example, procalcitonin, YKL-40 and surfactant protein-D,<sup>46 47</sup> molecular detection of respiratory pathogens,<sup>48</sup> and/or improved imaging modalities.<sup>12 14</sup>

This prospective study highlights the challenges in identifying patients with CAP based on patient history, vital signs and symptoms on admission.<sup>20 22 46</sup> An initial CAP diagnosis may often differ from the discharge diagnosis.<sup>10 49</sup> A plausible cause for uncertainty in diagnosing CAP was the heterogenic presentation of symptoms overlapping with other diseases. We found that patients with verified CAP often had gastrointestinal symptoms, whereas patients not verified with CAP sometimes presented with typical respiratory symptoms and had more severe conditions measured by CURB-65. Typical respiratory



**Table 3** The complete diagnostic model, including the intercept

Intercept and predictors	$\beta$ Coefficient
Intercept	-1.66192
Dyspnoea (yes)	0.35172
Expectoration (yes)	0.36250
Cough (yes)	0.39671
Common cold (yes)	0.34374
Malaise (yes)	0.07475
Chest pain (yes)	0.20499
Respiratory rate >20 breaths/min	0.14566
Oxygen saturation <96%	0.24303
Abnormal auscultation findings (yes)	0.56758
Leucocytes*	0.00322
Neutrophils†	0.08338
C reactive protein <20 mg/L	-0.64269
Previous event of CAP (no)	-0.12006
Age of $\geq 75$ and cough (yes)	0.53816
Age of $\geq 75$ and oedema (no)	-0.05797
Age of $\geq 75$ and glucose >11.0 mmol/L	0.88124
AUC (95% CI)	0.85 (0.77 to 0.92)

\*Cut-off for leucocytes: normal values  $3.5-8.8 \times 10^9/L$ .  
†Neutrophils:  $>7.5 \times 10^9/L$ .  
AUC, area under the curve; CAP, community-acquired pneumonia.

symptoms could explain some CAP misclassification. Misclassification of CAP may lead to unnecessary or ineffective antibiotic treatment, increased healthcare costs, delayed diagnosis, increased mortality and increased risk of bacterial resistance.<sup>44 50</sup>

The predictors of CAP identified in this study are strongly discussed in the literature.<sup>9 20 36 37 42 46 49</sup> Most prediction models for ED patients with CAP aim to predict prognostic outcomes such as disease severity and mortality.<sup>51</sup> Prior studies have either included few diagnostic predictors or very selected patients.<sup>20 22 52</sup> The main reason for including several potential predictors and having age as a cross-factor in the development of our model was the expectation of finding predictors not represented in the literature and predictors specific for older patients ( $\geq 75$  years). This is considered very relevant as the population worldwide ages.<sup>4 16</sup> An age of  $\geq 75$

interacted with the symptoms of cough, blood glucose levels and peripheral oedema. Peripheral oedema was associated with an absence of CAP, and symptoms may be explained by other infections, such as erysipelas or heart failure. In addition, hyperglycaemia has been recognised as a predictor associated with poorer patient outcomes for elderly patients with CAP, regardless of their history of diabetes.<sup>53 54</sup>

Even though the literature highlights malnutrition as a strong prognostic predictor for CAP,<sup>33 35 55</sup> we excluded BMI from our final model. Measuring weight and height is not a priority in acute settings where vital parameters, symptoms and point-of-care biomarkers are the primary observations in the diagnostic process. Another concern was that BMI was missing in 26.3% of the population, and bias may arise due to systematic differences between subjects with complete datasets and subjects with missing data. Patients with missing BMI data may be more frail, incapable or difficult to transfer. A model including BMI could be a better choice in a primary care setting, where patients are not necessarily as acutely ill and may be able to weigh themselves.

A major strength of this study is the completeness of data from medical charts and patient interviews combined with CAP diagnoses assigned by a panel of experts. The experts had a range of information from the patient's medical records, including chest X-ray, chest CT for patients suspected of CAP and microbiology results. In addition to identifying possible predictors, we included many relevant and easily accessible clinical parameters. Finally, we excluded patients infected with SARS-CoV-2 from the study to increase the potential generalisability for patients with CAP after the pandemic.

This study has limitations. Multiple testing and mass significance are potentially a problem in this study. Methods, such as Bonferroni-Holm correction, could have been applied to counteract this problem.<sup>56</sup> However, the univariate analyses were conducted for exploratory and descriptive purposes only. Therefore, these results should be interpreted cautiously, and the findings should be used as hypothesis-generating rather than conclusive. Another concern is that even though the reference standard of CAP was the same for the model performance and the initial diagnosis of the ED physicians, the expert panel may have had better opportunities to diagnose CAP in patients with suspected CAP due to the availability of results from imaging and microbiological tests, and

**Table 4** Performance of the predictive model compared with the initial diagnosis made by the ED physicians.

Performance	Sensitivity % (CI %)	Specificity % (CI %)	Positive predictive value % (CI %)	Negative predictive value % (CI %)
Predictive model	86.1 (79.1 to 93.1)	64.1 (57.1 to 71.1)	41.6 (34.6 to 48.6)	93.9 (86.9 to 100)
Physicians	86.4 (84.2 to 88.6)	74.9 (72.1 to 77.6)	57.0 (53.8 to 60.1)	93.5 (92.0 to 95.0)

The predictive model had a 35% cut-off and a prevalence of 22%. The prevalence of CAP was 28% in the population of 954 patients suspected of infection.  
CAP, community-acquired pneumonia.



better register of patient's symptoms. This could lead to differential verification bias overestimating the ED physician's accuracy in diagnosing CAP.<sup>57</sup> This assumption was supported by the higher specificity of CAP diagnoses from ED physicians.

Another limitation is the selected population of patients allocated to the internal medicine specialty that may have masked atypical predictors from patients assigned to other specialities. Furthermore, some patients with atypical clinical presentation may have an infection that the ED physician had not suspected on admission and, therefore, was not included in our study. Patients with severe conditions or acute cognitive impairment who could not consent were excluded. Furthermore, the inclusion of patients took place during work hours and weekdays, which may have reduced the number of severe cases as admission during out-of-hours and weekends are associated with increased mortality and ICU admissions.<sup>58</sup> Therefore, our results can only be generalised to patients suspected of CAP and admitted on weekdays during the daytime.

A broader patient inclusion may contribute to a model that identifies other predictors to diagnose CAP as the clinical presentation may differ from those admitted with suspected CAP and capable of consent. Another limitation was the pragmatic choice of cut-offs for blood tests routinely used in our institutions, which reflected our clinical practice. However, it does raise questions about the applicability in other settings that apply different cut-offs.

This population cohort could be applicable as a test validation cohort for future models as the data collection of these well-known predictors of CAP is reproducible across EDs. The development of automatic extraction for a prediction model from electronic medical records using artificial intelligence could be of great value in a busy ED. In conclusion, typical respiratory symptoms combined with abnormal vital signs and elevated infection biomarkers are predictors for CAP on admission to an ED. A diagnostic prediction model based on these predictors is of limited value. Future prediction models should include novel diagnostic tools, imaging, PCR analysis and/or serological markers not routinely used in clinical practice to improve model performance and diagnose CAP more accurately in the ED.

#### Author affiliations

<sup>1</sup>Department of Emergency Medicine, University Hospital of Southern Denmark, Aabenraa, Denmark

<sup>2</sup>Department of Regional Health Research, University of Southern Denmark, Odense, Denmark

<sup>3</sup>Department of Clinical Microbiology, Odense Universitetshospital, Odense, Denmark

<sup>4</sup>Research Unit of Clinical Microbiology, University of Southern Denmark, Odense, Denmark

<sup>5</sup>Department of Biochemistry and Immunology, University Hospital of Southern Denmark, Aabenraa, Denmark

<sup>6</sup>Department of Clinical Research, University of Southern Denmark, Odense, Denmark

<sup>7</sup>Department of Infectious Diseases, Odense University Hospital, Odense, Denmark

X Mariana B Cartuliales @MCartuliales

**Acknowledgements** The authors appreciate text editing from the research consultant Caroline Moos, statistician support from Andreas Kristian Pedersen and Sofie Ronja Petersen at the University Hospital of Southern Denmark, and from OPEN (Open Patient Data Explorative Network, Department of Clinical Research, University of Southern Denmark).

**Contributors** MBC, FSR, CBM, TAS, HS-A, MHL, AH and MAH were involved in the study's design. MBC performed the literature search and drafted the original work. MBC, MHL, AH, MAH, JJS and FK recruited patients and collected data. CBM and MAH participated in the expert panel. HS-A was the study investigator and coordinated and supervised the project. MBC performed the statistical analyses. CBM is the guarantor of the study and the chief research officer responsible for supervising the overall study. All authors, MBC, FSR, CBM, TAS, HS-A, MHL, AH, MAH, FK and JJS, critically revised and approved the final manuscript.

**Funding** The study is funded by University of Southern Denmark (17/10636) and University Hospital of Southern Denmark (20/20505). The funders of this study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** Approval was obtained from the Regional Committee for Health Research Ethics in Southern Denmark (S-20200188). In addition, informed verbal and written consent was obtained from each participant before enrolment in the study. This study was conducted in agreement with the Declaration of Helsinki-Ethical principle for medical research involving human subjects.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Due to Danish laws on personal data, data cannot be shared publicly. To request data, please contact the corresponding author for more information. The person responsible for the research was the principal investigator and corresponding author (MBC) in collaboration with the University Hospital of Southern Denmark. This organisation owns the data and can provide access to the final data set.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Mariana B Cartuliales <http://orcid.org/0000-0003-0923-6960>

#### REFERENCES

- Sogaard M, Nielsen RB, Schönheyder HC, *et al.* Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997-2011. *Respir Med* 2014;108:1214-22.
- McLaughlin JM, Khan FL, Thoburn EA, *et al.* Rates of hospitalization for community-acquired pneumonia among US adults: A systematic review. *Vaccine* 2020;38:741-51.
- Weite T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax* 2012;67:71-9.
- Laporte L, Hermetet C, Jouan Y, *et al.* Ten-year trends in intensive care admissions for respiratory infections in the elderly. *Ann Intensive Care* 2018;8:84.

- 5 GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and Aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. *Lancet Infect Dis* 2018;18:1191-210.
- 6 Meehan TP, Fine MJ, Krumholz HM, *et al.* Quality of care, process, and outcomes in elderly patients with pneumonia. *JAMA* 1997;278:2080-4.
- 7 Bell BG, Schellevis F, Stobberingh E, *et al.* A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infect Dis* 2014;14:13.
- 8 Metlay JP, Waterer GW, Long AC, *et al.* Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic society and infectious diseases society of America. *Am J Respir Crit Care Med* 2019;200:e45-67.
- 9 Musher DM, Thorner AR. Community-acquired pneumonia. *N Engl J Med* 2014;371:1619-28.
- 10 Chandra A, Nicks B, Maniago E, *et al.* A multicenter analysis of the ED diagnosis of pneumonia. *Am J Emerg Med* 2010;28:862-5.
- 11 Claessens Y-E, Debray M-P, Tubach F, *et al.* Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. *Am J Respir Crit Care Med* 2015;192:974-82.
- 12 Ye X, Xiao H, Chen B, *et al.* Accuracy of lung Ultrasonography versus chest radiography for the diagnosis of adult community-acquired pneumonia: review of the literature and meta-analysis. *PLoS ONE* 2015;10:e0130066.
- 13 Kamat IS, Ramachandran V, Eswaran H, *et al.* Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. *Clin Infect Dis* 2020;70:538-42.
- 14 Gentilotti E, De Nardo P, Cremonini E, *et al.* Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis. *Clin Microbiol Infect* 2022;28:13-22.
- 15 Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. *Arch Intern Med* 2008;168:351-6.
- 16 World Health Organization. Aging and health. 2022. Available: <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>
- 17 Weir DL, Majumdar SR, McAlister FA, *et al.* The impact of Multimorbidity on short-term events in patients with community-acquired pneumonia: prospective cohort study. *Clin Microbiol Infect* 2015;21:264.
- 18 Sakakibara T, Shindo Y, Kobayashi D, *et al.* A prediction rule for severe adverse events in all Inpatients with community-acquired pneumonia: a multicenter observational study. *BMC Pulm Med* 2022;22:34.
- 19 Gong L, He D, Huang D, *et al.* Clinical profile analysis and Nomogram for predicting in-hospital mortality among elderly severe community-acquired pneumonia patients with comorbid cardiovascular disease: a retrospective cohort study. *BMC Pulm Med* 2022;22:312.
- 20 Ding F, Han L, Yin D, *et al.* Development and validation of a simple tool composed of items on Dyspnea, respiration rates, and C-reactive protein for pneumonia prediction among acute febrile respiratory illness patients in primary care settings. *BMC Med* 2022;20:360.
- 21 Hammond A, Halliday A, Thornton HV, *et al.* Predisposing factors to acquisition of acute respiratory tract infections in the community: a systematic review and meta-analysis. *BMC Infect Dis* 2021;21:1254.
- 22 Ebell MH, Chupp H, Cai X, *et al.* Accuracy of signs and symptoms for the diagnosis of Community-Acquired pneumonia: a Meta-Analysis. *Acad Emerg Med* 2020;27:541-53.
- 23 Kitazawa T, Yoshihara H, Seo K, *et al.* Characteristics of pneumonia with negative chest radiography in cases confirmed by computed tomography. *J Community Hosp Intern Med Perspect* 2020;10:19-24.
- 24 Moons KGM, Altman DG, Reitsma JB, *et al.* Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med* 2015;162:W1-73.
- 25 Skjøt-Arkil H, Heltborg A, Lorentzen MH, *et al.* Improved diagnostics of infectious diseases in emergency departments: a protocol of a Multifaceted Multicentre diagnostic study. *BMJ Open* 2021;11:e049606.
- 26 Nørgaard B, Mogensen CB, Teglbjærg LS, *et al.* Diagnostic packages can be assigned accurately in emergency departments. A multi-centre cohort study. *Dan Med J* 2016;63:A5240.
- 27 Harris PA, Taylor R, Minor BL, *et al.* The Redcap consortium: building an international community of software platform partners. *J Biomed Inform* 2019;95:S1532-0464(19)30126-1:103208..
- 28 Mutepe ND, Cockeran R, Steel HC, *et al.* Effects of cigarette smoke condensate on Pneumococcal Biofilm formation and Pneumolysin. *Eur Respir J* 2013;41:392-5.
- 29 Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for pneumonia: a systematic review and meta-analysis. *Epidemiol Infect* 2010;138:1789-95.
- 30 Torres A, Peetermans WE, Viegi G, *et al.* Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax* 2013;68:1057-65.
- 31 Barbagelata E, Cillóniz C, Dominedò C, *et al.* Gender differences in community-acquired pneumonia. *Minerva Med* 2020;111:153-65.
- 32 Baik I, Curhan GC, Rimm EB, *et al.* A prospective study of age and Lifestyle factors in relation to community-acquired pneumonia in US men and women. *Arch Intern Med* 2000;160:3082-8.
- 33 Cillóniz C, Dominedò C, Pericàs JM, *et al.* Community-acquired pneumonia in critically ill very old patients: a growing problem. *Eur Respir Rev* 2020;29:0126-2019.
- 34 Reisinger EC, Fritzsche C, Krause R, *et al.* Diarrhea caused by primarily non-gastrointestinal infections. *Nat Clin Pract Gastroenterol Hepatol* 2005;2:216-22.
- 35 Riquelme O R, Riquelme O M, Rioseco Z ML, *et al.* Neumonía Adquirida en La Comunidad en El Anciano Hospitalizado: Aspectos Clínicos Y Nutricionales [Community-acquired pneumonia in the elderly: clinical and nutritional aspects]. *Rev Méd Chile* 2008;136:587-93.
- 36 Moore M, Stuart B, Little P, *et al.* Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. *Eur Respir J* 2017;50:1700434.
- 37 van Vugt SF, Broekhuizen BDL, Lammens C, *et al.* Use of serum C reactive protein and Procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. *BMJ* 2013;346:f2450.
- 38 Alam N, Vegting IL, Houben E, *et al.* Exploring the performance of the National early warning score (NEWS) in a European emergency Department. *Resuscitation* 2015;90:111-5.
- 39 Plesner LL, Iversen AKS, Langkjær S, *et al.* The formation and design of the TRIAGE study-baseline data on 6005 consecutive patients admitted to hospital from the emergency Department. *Scand J Trauma Resusc Emerg Med* 2015;23:106.
- 40 Ravioli S, Germann C, Gygli R, *et al.* Age- and sex-related differences in community-acquired pneumonia at presentation to the emergency Department: a retrospective cohort study. *Eur J Emerg Med* 2022;29:366-72.
- 41 Akhtar A, Hassali MAA, Zainal H, *et al.* Respiratory-tract infections among Geriatrics: prevalence and factors associated with the treatment outcomes. *Ther Adv Respir Dis* 2021;15:1753466620971141.
- 42 Metlay JP, Schulz R, Li YH, *et al.* Influence of age on symptoms at presentation in patients with community-acquired pneumonia. *Arch Intern Med* 1997;157:1453-9.
- 43 Dale AP, Marchello C, Ebell MH. Clinical Gestalt to diagnose pneumonia, sinusitis, and Pharyngitis: a meta-analysis. *Br J Gen Pract* 2019;69:e444-53.
- 44 Ray P, Birolleau S, Lefort Y, *et al.* Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. *Crit Care* 2006;10:R82.
- 45 Heckerling PS, Gerber BS, Tape TG, *et al.* Prediction of community-acquired pneumonia using artificial neural networks. *Med Decis Making* 2003;23:112-21.
- 46 Htun TP, Sun Y, Chua HL, *et al.* Clinical features for diagnosis of pneumonia among adults in primary care setting: A systematic and meta-review. *Sci Rep* 2019;9:7600.
- 47 Spoorenberg SMC, Vestjens SMT, Rijkers GT, *et al.* YKL-40, Ccl18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia. *Respirology* 2017;22:542-50.
- 48 Gastii N, Loubinoux J, Daragon M, *et al.* Multicentric evaluation of Biofire Filmarray pneumonia panel for rapid Bacteriological documentation of pneumonia. *Clin Microbiol Infect* 2021;27:1308-14.
- 49 Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. *Ann Intern Med* 2003;138:109-18.
- 50 Kanwar M, Brar N, Khatib R, *et al.* Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-H antibiotic administration rule. *Chest* 2007;131:1865-9.
- 51 Loke YK, Kwok CS, Niruban A, *et al.* Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. *Thorax* 2010;65:884-90.

- 52 Okimoto N, Yamato K, Kurihara T, *et al.* Clinical predictors for the detection of community-acquired pneumonia in adults as a guide to ordering chest Radiographs. *Respirology* 2006;11:322–4.
- 53 Zeng W, Huang X, Luo W, *et al.* Association of admission blood glucose level and clinical outcomes in elderly community-acquired pneumonia patients with or without diabetes. *Clin Respir J* 2022;16:562–71.
- 54 Barmanray RD, Cheuk N, Furlanos S, *et al.* In-hospital hyperglycemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): a systematic review and meta-analysis of observational studies prior to COVID-19. *BMJ Open Diabetes Res Care* 2022;10:e002880.
- 55 Yeo HJ, Byun KS, Han J, *et al.* Prognostic significance of malnutrition for long-term mortality in community-acquired pneumonia: a propensity score matched analysis. *Korean J Intern Med* 2019;34:841–9.
- 56 Sedgwick P. Multiple significance tests: the Bonferroni correction. *BMJ* 2011;344:e509.
- 57 Rutjes AWS, Reitsma JB, Di Nisio M, *et al.* Evidence of bias and variation in diagnostic accuracy studies. *CMAJ* 2006;174:469–76.
- 58 Vest-Hansen B, Riis AH, Sørensen HT, *et al.* Out-of-hours and weekend admissions to Danish medical departments: admission rates and 30-day mortality for 20 common medical conditions. *BMJ Open* 2015;5:e006731.